Today, we announced a strategic partnership with Genomenon to integrate its Mastermind Genomic Intelligence Platform and Cancer Knowledgebase (CKB) into the Golden Helix software suite. This collaboration combines two industry-leading platforms to enhance genomic interpretation and deliver high-confidence, literature-backed insights to clinical laboratories worldwide.
Through this integration, Golden Helix customers gain seamless access to Genomenon’s expertly curated germline and somatic content directly within VarSeq’s annotation engine. These new data layers are fully harmonized alongside trusted public sources like ClinVar, enabling streamlined filtering and prioritized variant interpretation for both inherited diseases and cancer.
“Golden Helix is a recognized leader in clinical genomics, and we’re proud to partner with them to deliver Genomenon’s rich, evidence-backed insights directly into their analysis workflows,” said Mike Klein, CEO of Genomenon. “This integration empowers labs to make faster, more confident clinical decisions by surfacing the most relevant scientific literature and curated genetic data exactly where and when it’s needed.”
“This partnership allows us to deliver deeply curated literature, pathogenicity insights, and oncology knowledge within the trusted Golden Helix framework our customers rely on every day,” said Dr. Andreas Scherer, President and CEO of Golden Helix. “By embedding the rich data and insights from Mastermind and the Cancer Knowledge-Base into our platform, we are accelerating the speed and enhancing the accuracy of clinical decision-making — ultimately enabling better outcomes for patients.”
Key Benefits of the Partnership
By integrating Genomenon’s Mastermind and Cancer Knowledgebase directly into the VarSeq Suite, Golden Helix customers can now access expertly curated genomic content for both inherited disease and cancers alongside their existing workflows. This powerful combination delivers high-confidence insights into variant pathogenicity, biomarker associations, therapeutic relevance, diagnostic criteria, and supporting literature — all within a familiar interpretation environment.
The seamless harmonization of Mastermind and CKB with VarSeq’s annotation engine enhances variant prioritization by unifying these premium sources with trusted public databases. This streamlined filtering enables labs to surface the most clinically relevant variants quickly and with greater confidence. As a result, clinical teams can significantly reduce manual curation time, accelerate turnaround, and produce evidence-backed reports with improved consistency and accuracy.
Importantly, this integration is designed for flexibility and scale. Whether deployed on-premises, in the cloud, or within hybrid infrastructures, Golden Helix continues to ensure enterprise-grade data control, security, and regulatory compliance — enabling diagnostic labs worldwide to meet the evolving demands of precision medicine.
